Kronos Bio Inc's Customers Performance

Name: Kronos Bio Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

KRON

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


KRON's Source of Revenues		During the corresponding time, Kronos Bio Inc saw a revenue deteriorated by -26.03 % year on year, sequentially revenue fell by -17.89 %. While revenue at the Kronos Bio Inc 's corporate clients • List of KRON Customers

for the same period Kronos Bio Inc revnue deteriorated by -26.03 % year on year, sequentially revenue fell by -17.89 %.

• List of KRON Customers

Kronos Bio Inc's Business Units

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Kronos Bio Inc's Comment on Sales, Marketing and Customers

News about Kronos Bio Inc Contracts

Kronos Bio Unveils Promising Autoimmune Candidate Amid Financial Struggles

Kronos Bio Inc. has announced a significant milestone in its development pipeline, unveiling KB-7898 as its inaugural candidate for autoimmune diseases, specifically targeting Sjögren’s disease. This candidate is a p300 KAT inhibitor, emerging from the company s proprietary discovery engine that effectively decodes intricate transcription factor regulatory networks. The selection marks a pivotal moment for Kronos Bio, as it seeks to navigate the challenging landscape of autoimmune therapeutics.Despite this promising advancement, the company faces considerable financial hurdles. In a recent report, Kronos Bio disclosed a cumulative net loss of $103 million for the twelve months ending in the second quarter...

Kronos Bio's Breakthroughs and Challenges: Advancing Precision Oncology with Promising AML Research and Unexpected Hurdles

In a recent pipeline update, Kronos Bio, a leading clinical-stage biopharmaceutical company, has made significant strides in their research and development efforts. While showcasing progress in their Phase 1b study for relapsed/refractory FLT3-mutated acute myeloid leukemia (AML), they also faced an unexpected hurdle in the advancement of their p300 KAT inhibitor development candidate. This article delves into the details of Kronos Bio s pipeline update, highlighting the successful completion of the Phase 1b portion of the lanraplenib study, as well as the decision not to proceed with Phase 2 based on review data.

Kronos Bio is at the forefront of pioneering treatments for life-threateni...

KRON's Stock Performance relative to it's Customers

KRON's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Kronos Bio Inc	53.51	9.19	-64.49	74
SUBTOTAL	0.00	0.00	0.00	-

Sources: Kronos Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Kronos Bio Inc’s corporate clients.
For your research, we’ve provided 9 tables on Kronos Bio Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.